Local controlled drug delivery for prolonged pain relief in joints
Upon an intra-articular application, biomaterials enabling controlled release of anti-inflammatory medication harness inflammation and mitigate pain. Through a unique pre-clinical platform employing small animal models and ultimately the veterinary patients suffering from osteoarthritis or back pain, we have been able to develop these strategies.
To feed these strategies with the appropriate biomolecules, we employ developmental biology and the divergence seen within the canine species to identify and validate regenerative targets by means of “omics”. Within this context, we also study how joint distraction facilitates intrinsic cartilage repair.
The OA-BIO project is a Eurostars project that proposes a novel disease modifying drug for OA, 4P-004, a new proprietary formulation of approved incretin mimetic (a Glucagon-Like Peptide-1 receptor agonist) Liraglutide for intra-articular administration. The game-changing treatment has a unique triple effect: anti-inflammation, anti-pain and cartilage regeneration; offering the first curative OA therapy. In this project, new OA imaging and liquid biopsy biomarkers (e.g. blood, urine and synovial fluid) will be validated. Moreover, different OA models will be used to monitor treatment response (efficacy) by measuring these OA-biomarkers during and after inducing OA related tissue responses.